| Sign In to gain access to subscriptions and/or personal tools. |
Racial Differences in the Impact of Comorbidities on Survival Among Elderly Men With Prostate CancerCenter for Clinical Epidemiology and Biostatistics, University of Pennsylvania, Philadelphia
School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Philadelphia VA Center for Health Equity Research and Promotion, Pennsylvania
School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia
School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Wharton School of Business, University of Pennsylvania, Philadelphia, Center for Outcomes Research, Children's Hospital of Philadelphia, Pennsylvania
School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Philadelphia VA Center for Health Equity Research and Promotion, Pennsylvania
School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia
School of Medicine, Leonard Davis Institute of Health Economics, and Wharton School of Business, University of Pennsylvania, Philadelphia
School of Medicine, University of Pennsylvania, Philadelphia, Robert Wood Johnson Clinical Scholars Program, University of Pennsylvania, Philadelphia, Philadelphia VA Center for Health Equity Research and Promotion, Pennsylvania
Leonard Davis Institute of Health Economics, University of Pennsylvania and Divisions of Population Science and Medical Science, Fox Chase Cancer Center, Philadelphia, Pennsylvania
School of Medicine and Leonard Davis Institute of Health Economics, University of Pennsylvania and Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, karmstro{at}mail.med.upenn.edu
This study investigates differences in the effects of comorbidities on survival in Medicare beneficiaries with prostate cancer. Medicare data were used to assemble a cohort of 65- to 76-year-old Black (n = 6,402) and White (n = 47,458) men with incident localized prostate cancer in 1999 who survived
Key Words: administrative data comorbidity disparities Medicare prostate cancer social epidemiology survival analysis
This version was published on August
1, 2009 Medical Care Research and Review, Vol. 66, No. 4,
409-435 (2009) |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 year postdiagnosis. Comorbidities were more prevalent among Blacks than among Whites. For both races, greater comorbidity was associated with decreasing survival rates; however, the effect among Blacks was smaller than in Whites. After adjusting for age, socioeconomic status, and community characteristics, the association between increasing comorbidities and survival remained weaker for Blacks than for Whites, and racial disparity in survival decreased with increasing number of comorbidities. Differential effects of comorbidities on survival were also evident when examining different classes of comorbid conditions. Adjusting for treatment had little impact on these results, despite variation in the racial difference in receipt of prostatectomy with differing comorbidity levels.